Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

The pharma giant said amycretin led to weight loss and diabetes reductions in both injection and pill versions.

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

New GLP-1 weight-loss drugs may preserve muscle, protect skin, and reduce the risk of "Ozempic face." Experts explain what ...

Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...